Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
lupus nephritis
Biotech
Adicet Bio CAR-T sparks lupus remissions in early-stage trial
Adicet's prula-cel sent more than half of patients’ lupus into remission, without the dangerous side effects that recently rocked Big Pharma.
Darren Incorvaia
Sep 28, 2026 6:45am
Cell therapy biotech Adicet sheds 30% of staffers
Jul 24, 2025 10:20am
Kezar sees hepatitis hold lifted, mulls restarting lupus program
Jul 16, 2025 8:47am
Nxera sells lupus drug's APAC rights to Viatris for $10M upfront
Feb 28, 2025 5:10am
Cabaletta's CAR-T shows 'robust benefit' in autoimmune patients
Feb 19, 2025 11:10am
AstraZeneca CEO defends 'fantastic' Alexion buy as halts drug
Feb 6, 2025 6:45am
